Clinical and Experimental Study on Probiotics in the Treatment of Constipation Type Irritable Bowel Syndrome

Biomarkers and applications Pub Date : 2019-09-27 DOI:10.29011/2576-9588.100038

Zeli Gao, J. Ji, Xiaotong He

{"title":"Clinical and Experimental Study on Probiotics in the Treatment of Constipation Type Irritable Bowel Syndrome","authors":"Zeli Gao, J. Ji, Xiaotong He","doi":"10.29011/2576-9588.100038","DOIUrl":null,"url":null,"abstract":"Aim: The effects of probiotics on symptoms scores, gastrointestinal hormones and oxidative stress index in constipative Irritable Bowel Syndrome (IBS-C) patients were studied-during the period of 2018. Methods: 96 patients with IBS-C who had been treated in our hospital previously. The patients in the control group (49) were treated with Mosapride, and the patients in the observation group (47) were treated with Bifidobacterium triple viable enteric-coated capsules on the basis of the control treatment. The clinical efficacy including: clinical symptoms, gastrointestinal hormones, 5-HT and oxidative stress were studied and compared between the two groups. Results: In the observation group, the clinical efficacy in 29 cases (61.70%) was markedly effective and in 15 cases (31.91%) moderately effective, in comparison the total effective rate was 93.62%in the observation group, and 79.59% in the control group (P < 0.05). After treatment, the clinical symptoms score in both two groups decreased significantly. The scores of abdominal distension, abdominal pain, defecation frequency, stool characteristics and defecation difficulty in the observation group were significantly lower than those in the control group (P < 0.05). Although the levels of 5-HT, MDA and LPO in both groups decreased significantly after treatment. The levels of 5-HT, MDA and LPO in the observation group were even lower than those in the control group (P < 0.05). Similarly, the levels of gastrointestinal hormones in both groups were improved with the respective treatments. However, the MTL level in the observation group was significant higher than that in the control group, and the levels of VIP and S were lower in the observation group than those in the control group (P < 0.05). Conclusion: Bifidobacterium triple viable capsule combined with Mosapride is more effective in the treatment of IBS-C. The combination therapy can better relieve symptoms, and further decreased gastrointestinal hormone levels and reduce oxidative stress response in IBS-C patients. It is therefore highly recommended for clinical application.","PeriodicalId":93081,"journal":{"name":"Biomarkers and applications","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2019-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biomarkers and applications","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.29011/2576-9588.100038","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 1

Abstract

Aim: The effects of probiotics on symptoms scores, gastrointestinal hormones and oxidative stress index in constipative Irritable Bowel Syndrome (IBS-C) patients were studied-during the period of 2018. Methods: 96 patients with IBS-C who had been treated in our hospital previously. The patients in the control group (49) were treated with Mosapride, and the patients in the observation group (47) were treated with Bifidobacterium triple viable enteric-coated capsules on the basis of the control treatment. The clinical efficacy including: clinical symptoms, gastrointestinal hormones, 5-HT and oxidative stress were studied and compared between the two groups. Results: In the observation group, the clinical efficacy in 29 cases (61.70%) was markedly effective and in 15 cases (31.91%) moderately effective, in comparison the total effective rate was 93.62%in the observation group, and 79.59% in the control group (P < 0.05). After treatment, the clinical symptoms score in both two groups decreased significantly. The scores of abdominal distension, abdominal pain, defecation frequency, stool characteristics and defecation difficulty in the observation group were significantly lower than those in the control group (P < 0.05). Although the levels of 5-HT, MDA and LPO in both groups decreased significantly after treatment. The levels of 5-HT, MDA and LPO in the observation group were even lower than those in the control group (P < 0.05). Similarly, the levels of gastrointestinal hormones in both groups were improved with the respective treatments. However, the MTL level in the observation group was significant higher than that in the control group, and the levels of VIP and S were lower in the observation group than those in the control group (P < 0.05). Conclusion: Bifidobacterium triple viable capsule combined with Mosapride is more effective in the treatment of IBS-C. The combination therapy can better relieve symptoms, and further decreased gastrointestinal hormone levels and reduce oxidative stress response in IBS-C patients. It is therefore highly recommended for clinical application.

查看原文本刊更多论文

益生菌治疗便秘型肠易激综合征的临床与实验研究

目的：研究2018年期间益生菌对便秘型肠易激综合征（IBS-C）患者症状评分、胃肠激素和氧化应激指数的影响。方法：对我院收治的96例IBS-C患者进行回顾性分析。对照组（49）患者用莫沙必利治疗，观察组（47）患者在对照治疗的基础上用双歧杆菌三联活肠溶胶囊治疗。研究两组患者的临床疗效，包括临床症状、胃肠激素、5-羟色胺和氧化应激。结果：观察组显效29例（61.70%），中效15例（31.91%），总有效率观察组为93.62%，对照组为79.59%（P<0.05），治疗后两组临床症状评分均明显下降。观察组的腹胀、腹痛、排便次数、大便特征和排便困难评分均显著低于对照组（P<0.05），但治疗后两组的5-HT、MDA和LPO水平均显著下降。观察组的5-HT、MDA和LPO水平甚至低于对照组（P＜0.05），两组的胃肠激素水平也均有改善。观察组MTL水平明显高于对照组，VIP和S水平明显低于对照组（P<0.05）。联合治疗可以更好地缓解炎症综合征患者的症状，并进一步降低胃肠激素水平和减少氧化应激反应。因此，强烈建议临床应用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Biomarkers and applications

自引率

0.00%

发文量